HK Inno.N's sales and operating profit declined significantly in Q2 this year. This can be attributed to the sharp decline in MSD vaccine sales amid brisk earnings of its flagship product, K-Cab (tegoprazan),.

HK InnoN explained that shipments of Gardasil, its cervical cancer vaccine, were concentrated in the second quarter of last year before the company’s price hike, and the resulting base effect occurred in Q2 this year.

According to the Financial Supervisory Service on the 1st, HK Inno.N's sales in Q2 were KRW 204.4 billion, down 18.9% YoY from the KRW 251.9 billion it posted in the second quarter of last year. During the same period, the company’s operating profit decreased by 13.